2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Checkpoint Inhibitor, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Patient-Reported Outcomes, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2054 Convergent silencing of the PHF20 chromatin writer defines a druggable HDAC2 dependency beyond del(20q)

Mark David Orland, MD, PhD, Nandini Rajaram Siva, MD2, Luca Guarnera, MD3, Kartik Lakhotiya, MS4, Carlos Bravo-Perez, MD5, Atsushi Marumo, MD6, Zachary Brady, BS7, Carmelo Gurnari, MD,PhD8, Valeria Visconte, PhD9, Jaroslaw P. Maciejewski, MD, PhD, FACP10
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
2 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
4 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, University of Murcia, IMIB-Pascual Parrilla, CIBERER - Instituto de Salud Carlos III, Murcia, Spain
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States

Background: Deletions of chromosome 20q are among the most common cytogenetic abnormalities in myeloid neoplasms. Multiple haploinsufficient genes, including L3MBTL1, MYBL2, and EIF6, have each been shown to recapitulate components of the characteristic del(20q) phenotype in vitro. However, these studies have largely identified individual candidate genes without defining a convergent regulatory mechanism that creates a therapeutically exploitable vulnerability. We therefore integrated multi-network systems biology with functional validation to identify the dominant regulatory drivers of del(20q).

Methods and Results: We analyzed 79 patients with del(20q) using paired SNP-array, RNA sequencing, and targeted NGS. Across the commonly deleted interval (20q11.22-q13.13), encompassing 126 genes, 101 exhibited reduced expression relative to diploid controls, while 69 demonstrated expression proportional to clonal burden, consistent with dosage-sensitive haploinsufficiency. We integrated clonality, differential expression, protein-protein interaction networks, and PANDA-derived regulatory inference to identify convergent regulatory hubs within the deleted interval. Although several genes including L3MBTL1, MYBL2, and EIF6 were dosage-sensitive, none emerged as dominant network regulators. Instead, we discovered PHF20 to be the highest-ranking regulatory hub. PHF20 is a core subunit of the MOF/NSL (KAT8) acetyltransferase complex that deposits H4K16 acetylation, the mark that decompacts chromatin and permits myeloid maturation, predicting that PHF20 haploinsufficiency collapses H4K16ac and arrests differentiation.

Functional validation demonstrated that PHF20 haploinsufficiency recapitulates key biological features of del(20q). siRNA-mediated knockdown in myeloid cell lines (K562, THP-1, TF-1) and healthy-donor CD34+ hematopoietic progenitors increased proliferation, rendered TF-1 cells GM-CSF independent, expanded clonogenic potential (CFU-GM 1.7-fold, P=0.02; BFU-E/CFU-E 2.2-fold, P=0.04), and reproduced erythroid-predominant dysplasia. Immunophenotyping demonstrated persistence of immature CD34-positive progenitors with impaired acquisition of CD11b, establishing differentiation arrest as the principal cellular consequence of PHF20 loss. Western blotting and immunofluorescence confirmed reduced PHF20 protein accompanied by global loss of H4K16 acetylation, validating destabilization of the PHF20-dependent chromatin acetylation program.

Transcriptomic analysis demonstrated an inverse relationship between PHF20 and HDAC2 (r²=0.40, P=0.047), with PHF20-low cases showing reciprocal upregulation of HDAC2, indicating that loss of the PHF20-associated acetyltransferase module creates dependence on the opposing deacetylase. Beat AML pharmacogenomic analysis (wave 1-2; 122 compounds) identified HDAC inhibitors as the drug class most strongly associated with low PHF20 expression. Consistent with this prediction, in Beat AML ex vivo studies, panobinostat demonstrated preferential activity in primary del(20q) specimens (ΔAUC +0.17), providing functional evidence that restoration of acetylation may reverse the consequences of PHF20 loss.

Importantly, reduced PHF20 expression was not unique to chromosome 20q deletion. Among 994 cytogenetically diploid AML cases, 51 PHF20-low leukemias (mRNA z ≤ −1.5) phenocopied del(20q), exhibiting increased HDAC2 expression (1.62-fold, 95% CI 1.48–1.76), thrombocytopenia (79 versus 109 ×10?/L), inferior survival (9.6 versus 12.2 months), and approximately two-fold greater TP53 mutation frequency (18% versus 8%). These findings suggest that genetically diverse myeloid neoplasms converge on suppression of PHF20 through mutation-driven mechanisms, creating the same HDAC2-dependent chromatin state independent of chromosome 20q deletion.

Conclusions: Multi-network regulatory analysis identified PHF20 as a central haploinsufficient regulator of del(20q), establishing an epigenetic dependency not apparent from previously recognized candidate genes. Importantly, suppression of PHF20 extends beyond chromosome 20q deletion, indicating that genetically diverse myeloid neoplasms converge on a shared PHF20-low, HDAC2-dependent chromatin state. These findings redefine PHF20 as both a biomarker and therapeutically actionable vulnerability, expanding the rationale for HDAC-directed therapy beyond cytogenetically defined del(20q).

Mark David Orland, MD, PhD: No relevant conflicts of interest to declare.